Abstract
Premalignant breast disease in humans is a concept that admits to a broad range of elements and possible determinants predicting the likelihood of developing breast cancer. Most of these elements are relative, such as the risk of breast cancer for women that is 130 times that of men and peaks at a younger age by about 10 years. Breast cancer is clearly a stochastic, multifactorial process that evolves over many years in which we must make predictions by likelihood. This review will present the most specially defined and reliably proven of these elements, highlighting anatomic and molecular factors.
Similar content being viewed by others
REFERENCES
P. L. Fitzgibbons, D. E. Henson, and R. V. P. Hutter (1998). Benign breast changes and the risk for subsequent breast cancer— Anupdate of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch. Pathol. Lab. Med. 122:1053–1055.
J. L. Kelsey (1993). Breast cancer epidemiology: Summary and future directions. Epidemiol. Rev. 15:256–263.
D. L. Page and W.D. Dupont (1998). Benign breast diseases and premalignant breast disease. Arch. Pathol. Lab. Med. 122:1048–1050.
R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike (2000). Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin [In Process Citation]. J. Natl. Cancer. Inst. 92:328–332.
W. D. Dupont and D. L. Page (1985). Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 312:146–151.
D. L. Page, W. D. Dupont, L. W. Rogers, and M. S. Rados (1985). Atypical hyperplastic lesions of the female breast. A long-follow-up study. Cancer 55:2698–2708.
D. L. Page and W. D. Dupont (1990). Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326–1335.
S. J. London, J. L. Connolly, S. J. Schnitt, and G. A. Colditz (1992). A prospective study of benign breast disease and risk of breast cancer. JAMA 267:941–944.
D. L. Page, W.D. Dupont, L.W. Rogers, R.A. Jensen, and P. A. Schuyler (1995). Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197–1200.
M. J. Silverstein, M. D. Lagios, S. Groshen, J. R. Waisman, B. S. Lewinsky, S. Martino, P. Gamagami, and W. J. Colburn (1999). The influence of margin width on local control of ductal carcinoma in situ of the breast. N. Engl. J. Med. 340:1455–1461.
C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton and R. Hoover (2000). Menopausal estrogen and estrogenprogestin replacement therapy and breast cancer risk. JAMA 283:485–491.
W. D. Dupont, D. L. Page, F. F. Parl, W. D. Plummer, Jr., P. A. Schuyler, M. Kasami, and R. A. Jensen (1999). Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85:1277–1283.
J. M. Dixon, C. McDonald, R. A. Elton, W. R. Miller (1999). Risk of breast cancer in women with palpable breast cysts: A prospective study. Edinburgh Breast Group. Lancet 353:1742–1745.
J. M. Dixon and R. E. Mansel (1994). ABC of breast diseases: Congenital problems and aberrations of normal breast development and involution. Brit. Med. J. 309:797–800.
W.D. Dupont, D. L. Page, F.F. Parl, J.C. Vnenck, W. J. Plummer, M. S. Rados, and P. A. Schuyler (1994). Long-term risk of breast cancer in women with fibroadenoma. N. Engl. J. Med. 331:10–15.
N. F. Boyd, H. M. Jensen, G. Cooke, H. L. Han, G. A. Lockwood, and A. B. Miller (2000). Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. Eur. J. Cancer. Prev. 9:15–24.
A. M. Oza and N. F. Boyd. (1993). Mammographic parenchymal patterns: A marker of breast cancer risk. Epidemiol. Rev. 15:196–208.
D. L. Page, R.A. Jensen, and J. F. Simpson (1998). Premalignant and malignant disease of the breast:The roles of the pathologist. Mod. Pathol. 11:120–128.
R. A. Jensen, D. L. Page, W. D. Dupont, and L. W. Rogers (1989). Invasive breast cancer risk in women with sclerosing adenosis. Cancer 64:1977–1983.
T.W. Jacobs, C. Byrne, G. Colditz, J. L. Connolly, and S. J. Schnitt (1999). Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N. Engl. J. Med. 340:430–436.
D. L. Page and J. F. Simpson (1999). Ductal carcinoma in situ— the focus for prevention, screening, and breast conservation in breast cancer. N. Engl. J. Med. 340:1499–1500.
J. N. Marcus, P. Watson, D. L. Page, S. A. Narod, G. M. Lenoir, P. Tonin, L. Linder-Stephenson, G. Salerno, T. A. Conway, and H. T. Lynch (1996). Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage [see comments]. Cancer 77:697–709.
L. M. Marshall, D. J. Hunter, J. L. Connolly, S. J. Schnitt, C. Byrne, S. J. London, and G. A. Colditz (1997). Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol. Biomarkers Prev. 6:297–301.
J. N. Marcus, P. Watson, D. L. Page, S.A. Narod, P. Tonin, G. M. Lenoir, O. Serova, and H. T. Lynch (1997). BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res. Treat. 44:275–277.
D. Weinstat-Saslow, M. J. Merino, R. E. Manrow, J. A. Lawrence, R. F. Bluth, K. D. Wittenbel, J. F. Simpson, D. L. Page, and P. S. Steeg (1995). Overexpression of cyclinDmRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat. Med. 1:1257–1260.
H.M. Jensen, J. R. Rice, and S. R. Wellings (1976). Preneoplastic lesions in the human breast. Science 191:295–297.
S. R. Wellings, H. M. Jensen, and R. G. Marcum (1975). An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer Inst. 55:231–273.
D. L. Page, T. E. Kidd, W. D. Dupont, J. F. Simpson, and L. W. Rogers (1991). Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. Hum. Pathol. 22:1232–1239.
D. L. Page and L. W. Rogers (1992). Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol. 23:1095–1097.
B. Fisher, J. Dignam, N. Wolmark, D. L. Wickerham, E. R. Fisher, E. Marounas, R. Smith, M. Begovic, N. V. Dimitrov, R. G. Margolese, C. G. Kardinal, M. T. Kavanah, L. Fehrenbacher, and R. H. Oishi (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 353:1993–2000.
M. Kasami, C. L. Vnencak-Jones, S. Manning, W. D. Dupont, and D. L. Page (1997). Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Amer. J. Pathol. 150:1925–1932.
H. Gobbi, W. D. Dupont, J. F. Simpson, W. D. Plummer, Jr., P. A. Schuyler, S. J. Olson, C. L. Arteaga, and D. L. Page (1999). Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl Cancer Inst. 91:2096–2101.
A. Stark, B. S. Hulka, S. Joens, D. Novotny, A. D. Thor, L. E. Wold, M. J. Schell, L. J. Melton, 3rd, E. T. Liu, and K. Conway (2000). HER–2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 18:267–274.
T. E. Rohan, W. Hartwick, A. B. Miller, and R. A. Kandel (1998). Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk [see comments]. J. Natl. Cancer Inst. 90:1262–1269.
D. C. Allred and S.G. Hilsenbeck (1998). Biomarkers in benign breast disease: Risk factors for breast cancer. J. Natl. Cancer Inst. 90:1247–1248.
D. L. Page, W. D. Dupont, and L.W. Rogers (1988). Ductal involvement by cells of atypical lobular hyperplasia in the breast: A long-term follow-up study of cancer risk. Hum. Pathol. 19:201–207.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Page, D.L., Jensen, R.A., Simpson, J.F. et al. Historical and Epidemiologic Background of Human Premalignant Breast Disease. J Mammary Gland Biol Neoplasia 5, 341–349 (2000). https://doi.org/10.1023/A:1009521726605
Issue Date:
DOI: https://doi.org/10.1023/A:1009521726605